<DOC>
	<DOC>NCT01854918</DOC>
	<brief_summary>This study will contribute to the evaluation of long-term safety, tolerability and efficacy of evolocumab (AMG 145) in subjects with hyperlipidemia and subjects with mixed dyslipidemia.</brief_summary>
	<brief_title>Open Label Study of Long Term Evaluation Against LDL-C Trial-2</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<criteria>Complete a qualifying evolocumab (AMG 145) parent study Experienced a treatmentrelated serious adverse event that led to IP discontinuation in the parent study Have an unstable medical condition, in the judgment of the investigator Known sensitivity to any of the products to be administered during dosing Currently enrolled in another investigational device or drug study (excluding evolocumab (AMG 145) parent study), or less than 30 days since ending another investigational device or drug study(s),or receiving other investigational agent(s)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>High cholesterol</keyword>
	<keyword>Raised cholesterol</keyword>
	<keyword>Cholesterol</keyword>
	<keyword>Elevated Cholesterol</keyword>
</DOC>